Drug intelligence / Profile preview

LX109

Development stage: Phase 1
Lead developer: Shanghai General Hospital
Modality: Gene Therapies
Administration: Intravitreal

Overview

LX109 is an investigational gene therapy being developed for the treatment of neovascular (wet) age-related macular degeneration (nAMD). It is administered via intravitreal injection and is currently being evaluated in exploratory clinical trials to assess its safety and tolerability in patients with nAMD. The therapy is under development by Shanghai First People's Hospital. The precise molecular target and mechanism of action have not been publicly disclosed as of the latest available information[1][7].

Beyond the preview

Go deeper on LX109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LX109.

Explore the full profile